Cancer de prostate : actualités 2008 : Prostate cancer: news in 2008

25 septembre 2008

Auteurs : L. Salomon, A. Descazeaud
Référence : Prog Urol, 2008, 18, S116, suppl. S6


Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser






Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2007 CA Cancer J Clin 2007 ;  57 : 43-66 [cross-ref]
incidence. Accessed 2007.
Boyle P., Ferlay J. Cancer incidence and mortality in Europe, 2004 Ann Oncol 2005 ;  16 : 481-488 [cross-ref]
Buschemeyer W.C., Freedland S.J. Obesity and prostate cancer: epidemiology and clinical implications Eur Urol 2007 ;  52 : 331-343 [cross-ref]
Larre S., Cancel-Tassin G., Azzouzi A.R., Cormier L., Vilette J.M., Hoffman P., et al. Influence of obesity on PSA levels on a screened population Eur Urol Suppl 2007 ;  6 : 177(abstract no. 618).  [cross-ref]
Murtola T., Tammela T., Määttänen L., Auvinen A. Prostate cancer and serum PSA among users of serum lipid-lowering drugs in the Finnish Prostate Cancer Screening Trial Eur Urol Suppl 2007 ;  6 : 223(abstract no. 803).
Tsang W., Roberts I., Brewster S. Are 2 repeat prostate biopsies sufficient to determine outcome of high-grade PIN and ASAP on initial prostate biopsy? Eur Urol Suppl 2007 ;  6 : 123(abstract no. 402).  [cross-ref]
Pallwein L., Friedrich A., Pallwein E., Mitterberger M., Bartsch G., Frauscher F. Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection Eur Urol Suppl 2007 ;  6 : 196(abstract no. 693).  [cross-ref]
Raber M., Scattoni V., Roscigno M., Dehò F., Abdollah F., Gallina A., et al. Extended 24-sample TRUS prostatic needle biopsy protocol for prostate cancer detection as initial diagnostic strategy Eur Urol Suppl 2007 ;  6 : 197(abstract no. 697).  [cross-ref]
Giannarini G., Mogorovich A., Valent F., Morelli G., De Maria M., Manassero F., et al. Continuing or discontinuing low-dose aspirin prior to transrectal prostate biopsy? Results of a prospective randomized trial Eur Urol Suppl 2007 ;  6 : 198(abstract no. 703).  [cross-ref]
Martorana G., Schiavina R., Brunocilla E., Concetti S., Bertaccini A., Manferrari F., et al. 11C-Choline- PET/CT for preoperative N-staging in high risk prostate cancer Eur Urol Suppl 2007 ;  6 : 89(abstract no. 266).  [cross-ref]
Eschmann S.M., Schilling D., Pfannenberg C., Rieger A., Lichy M.P., Claussen C.D., et al. Clinical staging and re-staging in prostate cancer:comparison of 11C-Choline-PET/CT and whole body MRI Eur Urol Suppl 2007 ;  6 : 89(abstract no. 267).  [cross-ref]
Zelhof B., Turnbull L., Cooksey G. The accuracy of 3T MRI for staging prostate cancer pre-operatively Eur Urol Suppl 2007 ;  6 : 89(abstract no. 268).  [cross-ref]
Roemeling S., Gosselaar C., Wolters T., Roobol M.J., Bangma C.H., Schröder F.H. Outcome of screen-detected prostate cancer patients who could have been considered for active surveillance Eur Urol Suppl 2007 ;  6 : 279(abstract no. 1027).  [cross-ref]
Porter C., Walz J., Gallina A., Jeldres C., Kodama K., Gibbons R., et al. Natural history of biochemical recurrence after radical prostatectomy for prostate cancer Eur Urol Suppl 2007 ;  6 : 181(abstract no. 634).  [cross-ref]
Hernandez D.J., Nielsen M.E., Chuang A.-Y., Han M., Partin A.W., Walsh P.C., et al. Cancer control following radical prostatectomy in men with capsular incision J Urol 2007 ;  177 : 249-250(abstract no. 744).
Chuang A.Y., Nielsen M.E., Hernandez D.J., Walsh P.C., Epstein J.I. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy J Urol 2007 ;  178 : 1306-1310 [cross-ref]
Boorjian S.A., Thompson R.H., Siddiqui S.A., Bagniewski S.M., Frank I., Blute M.L. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the PSA era J Urol 2007 ;  177 : 242-243(abstract no. 723).
Boorjian S.A., Thompson R.H., Siddiqui S., Bagniewski S., Bergstralh E.J., Karnes R.J., et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era J Urol 2007 ;  178 : 864-870 [cross-ref]
Deger S., Böhmer D., Johannsen M., Badakhshi H., Wille A., Roigas J., et al. Radiation and long-term hormonal therapy for patients with prostate cancer and pathologically confirmed lymph node metastases Eur Urol Suppl 2007 ;  6 : (abstract no. 255).
Cathelineau X., Jaffe J.S., Soon S.J., Rozet F., Barret E., Mombet A., et al. Laparoscopic radical prostatectomy:5 year oncologic results J Urol 2006 ;  177 (4 suppl) : (abstract no. 555).
Schachter L.R., Herrell S.D., Baumgartner R., Dietrich M.S., Cookson M.S., Chang S.S., et al. Early and delayed return of urinary continence after radical prostatectomy: results of a prospective comparative trial of an open retropubic vs. robotic approach J Urol 2006 ;  177 (4 suppl) : (abstract no. 1605).
Gaston K.E., Spiess P.E., Frey K., Urbauer D.L., Pisters L.L. Salvage prostatectomy in the modern PSA era:the M.D. Anderson experience J Urol 2007 ;  177 (590) : (abstract no. 1775).
Heidenreich A., Pfister D., Thüer D., Wille S., Engelmann U.H. Prognostic risk factors to predict final pathohistology in patients undergoing radical salvage prostatectomy for locally recurrent prostate cancer after radiation therapy Eur Urol Suppl 2007 ;  6 : (abstract no. 1039).
Viterbo R., Josephson D.Y., Nelson R.A., Yoshida J.S., Chan K.G., Crocitto L.E., et al. Radiation resistant prostate cancer: a single institution experience with laparoscopic and robotic salvage prostatectomy J Urol 2007 ;  177 (4 suppl) : (abstract no. 1600).
Guimaraes M., Soares A., Reis F., Oliveira R., Pina F., Sousa T., et al. Treatment of male stress urinary incontinence with the bone-anchored perineal sling Eur Urol Suppl 2007 ;  6 : 74(abstract no. 205).  [cross-ref]
Hage B., Hanna S., Schnutz G., Carmel M., Ponsot Y., Tu L.M. Male sling for moderate to severe stress urinary incontinence:efficacy and mechanism Eur Urol Suppl 2007 ;  6 : 74(abstract no. 206).  [cross-ref]
Verrini G., Borelli A., De Luca G., Peracchia G., Gavioli M., Viola M., et al. The use of InVance, the male sling system, in patients with stress urinary incontinence (SUI) post radical prostatectomy (RP):1 year follow-up Eur Urol Suppl 2007 ;  6 : 74(abstract no. 208).  [cross-ref]
D’Ancona C., Reges R., Palma P., Riccetto C., Netto N.R. Evaluation of male sling and health related quality of life for stress urinary incontinence: are the long term results maintained? Eur Urol Suppl 2007 ;  6 : 73(abstract no. 204).
Kocjancic E., Crivellaro S., Ranzoni S., Frea B. Surgical treatment of male urodynamic stress urinary incontinence:adjustable continence therapy Eur Urol Suppl 2007 ;  6 : 75(abstract no. 211).  [cross-ref]
Hampel C., Gillitzer R., Wiesner C., Thü roff J.W. Complication management and risk factors of the ProACT system for treatment of male stress incontinence Eur Urol Suppl. 2007 ;  6 : 75(abstract no. 212).  [cross-ref]
Otto T., Eimer C., Bagner J., Gerullis H., Schwartmann K., Bornemeyer K. Tissue engineering with autologous unipotent skeletal muscle cells in external sphincter insufficiency III Eur Urol Suppl 2007 ;  6 : (abstract no. 203).
Choe K.S., Jani A.B., Liauw S.L. Should Radiation Therapy be Modified for Prostate Cancer Patients on Anticoagulants? Int J Radiat Oncol Biol Phys 2007 ;  69 : S313(abstract no. 2201).
Ben-yosef R., Paz A., Levy Y., Muchner Y., Shohat S., Corn B., et al. Protecting the Rectum During Prostate Cancer Irradiation: A Development of a Degradable Implanted Device Int J Radiat Oncol Biol Phys 2007 ;  69 : S351(Abstract no. 2266).
Beckendorf V., Guerif S., Le Prise E., Cossett J.M., Le Floch O., Chauvet B., et al. Late Toxicity in the GETUG 06 Randomized Trial Comparing 70 Gy and 80 Gy for Localized Prostate Cancer Int J Radiat Oncol Biol Phys 2007 ;  69 : S319(Abstract no. 2210).
Parikh P.J., Bae K., Hanks G.E., Shipley W.U., Pilepich M.V., Sandler H.M. The Influence of Age as a Predictor of Outcome in Prostate Cancer Patients Treated on RTOG Trials Int J Radiat Oncol Biol Phys 2007 ;  69 : S175(Abstract no. 1069).
Shippy A.M., Katz M.S., Yamada Y., Feder D.J., Zelefsky M.J. Statin use and Clinical Outcomes After High Dose Radiotherapy for Prostate Cancer Int J Radiat Oncol Biol Phys 2007 ;  69 : S113(Abstract no. 203).
Mierzwa M.L., Barrett W.L., Redmond K.P., Shirazi R., Kastl A. A Phase III Randomized Trial to Assess the Efficacy of Intraoperative Steroid Use in Decreasing Acute Urinary Retention Following Transperineal Radioactive Seed Implantation for Prostate Cancer Int J Radiat Oncol Biol Phys 2007 ;  69 : S113(Abstract no. 204).
Huyghe E., Nohra J., Delavierre D., Delaunay B., Delannes M., Soulie M., et al. Erectile function after brachytherapy for localised prostate cancer:long-term results Eur Urol Suppl 2007 ; 6(abstract no. 736).
Venkatesan V., Abdelhady M., Elmaadawi A., McKenna A.M., Winquist E., Rodrigues G.B., et al. Comparison of Health Related Quality of Life (HRQOL) in Men Treated With Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer Int J Radiat Oncol Biol Phys 2007 ;  69 : S28(Abstract no. 49).
Spiotto M.T., Hancock S., King C.R. Improved Biochemical Relapse-Free Survival With Whole Pelvic Compared to Prostate Bed Only Radiotherapy for High-Risk Patients After Prostatectomy Int J Radiat Oncol Biol Phys 2007 ;  69 : S173(Abstract no. 1065).
Blana A., Thuüroff S., Murat F.J., Walter B., Chaussy C., Gelet A. Long-term results with high intensity focused ultrasound (HIFU) in 140 patients with localized prostate cancer Eur Urol Suppl 2007 ;  6 : 199(abstract no. 708).  [cross-ref]
Bolla M., van Tienhoven G., de Reijke T.M., van den Bergh A.C., van der Meijden A.P., Poortmans P.M., et al. EORTC Radiation Oncology and Genito-Urinary TractCancer Groups. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961 J Clin Oncol 2007 ;  25 (Suppl) : (abstract no. 5014).
Souhami L., Bae K.M., Pilepich M.V., Sandler H. The impact of the duration of adjuvant hormonal therapy in patients with unfavorable prognosis prostate cancer treated with radiotherapy: Secondary analysis of RTOG 85-31 J Clin Oncol 2007 ;  25 (Suppl) : (abstract no. 5062).
Yoon F., Choo R., Gardner S.L., Morton G., Szumacher F., Cheung P., et al. Testosterone recovery after two years of androgen suppression in prostate cancer patients J Clin Oncol 2007 ;  25 (Suppl) : (abstract no. 5044).
Siddiqui SA, Boorjian SA, Inman BA, Siezak JM, Blute ML. Timing and androgen deprivation therapy and its impact on cancer-specific survival after radical prostatectomy:a matched-cohort analysis. J Urol 177, 4 suppl. (abstract no. 601).
Tunn U.W., Canepa G., Hillger H., Fuchs W. Intermittent androgen deprivation in patients with PSA-release after radical prostatectomy. Final results of a European randomized prospective phase-III clinical trial AUO study AP 06/95, EC 507 J Urol 2007 ;  177 (4) : (abstract no. 600).
Miller K., Steiner A., Lingnau A., Keilholz U., Witzsch U., Haider A., et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer J Clin Oncol 2007 ;  25 (Suppl) : 238s(abstract no. 5015).
Gallina A., Karakiewicz P.I., Walz J., Jeldres C., Trinh Q.D., Traumann M., et al. Increased risk of newly diagnosed comorbidities in prostate cancer patients treated with androgen deprivation therapy J Urol 2007 ;  177 (200) : (abstract no. 598).
Efstathiou J.A., Bae K., Shipley W.U., Hanks G.E., Pilepich M.V., Sandler H.M., et al. Cardiovascular Mortality Following Androgen Deprivation Therapy in Men With Locally Advanced Prostate Cancer: An Analysis of RTOG 85-31 Int J Radiat Oncol Biol Phys 2007 ;  69 : S170(Abstract no. 1060).
Wadhwa V., Weston R., Parr N. A large proportion of patients with advanced prostate cancer continue to die of non-cancer causes after 5 years follow-up Eur Urol Suppl 2007 ;  6 : 87(abstract no. 259).  [cross-ref]
Moreno J., DeBono J.S., Shaffer D., Montgomery B., Miller M.C., Tissing H., et al. Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC) J Clin Oncol 2007 ;  25 (Suppl) : (abstract no. 5016).
Graff J., Lalani A.S., Lee S., Curd J.G., Henner W.D., Ryan C.W., et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial J Clin Oncol 2007 ;  25 (Suppl) : 253s(abstract no. 5074).
Petrylak D.P., Schellhammer P.F., Small E.J., Frohlich M.W. Androgen independent prostate cancer patients who receive sipuleucel-T followed by docetaxel have prolonged survival J Urol 2007 ;  177 (4 suppl) : (abstract no. 605).
Attard G., Yap T.A., Reid A.H., Parker C., Barrett M., Raynaud F., et al. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRCP) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor J Clin Oncol 2007 ;  25 (Suppl) : 250s(abstract no. 5063).
Ryan C.J., Rosenberg J., Lin A., Valiente J., Kime J., Small E.J. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgenindependent prostate cancer (AiPC) J Clin Oncol 2007 ;  25 (Suppl) : 250s(abstract no. 5064).
Boccardo F., Rubagotti A., Tacchini L., Lapini A., Cruciani G., De Rubertis G, et al. Gefinitib (G) plus prednisone (P) versus placebo (pl) plus prednisone in the treatment of hormone-refractory prostate cancer (HRPC): a randomized phase II trial. J Clin Oncol 2007 ;  25 (Suppl) : 252s.(abstract no. 5070).
Sternberg C.N., Petrylak D., Witjes F., Ferrero J., Eymard J., Falcon S., et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC:results of a randomized phase III trial J Clin Oncol 2007 ;  25 (Suppl) : 239s(abstract no. 5019).


© 2008  Elsevier Masson SAS. Tous droits réservés.